Bright Minds Biosciences Inc.
DRUG
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 427.80K | 471.10K | 381.80K | 255.40K | 234.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -186.40K | -- | -- | -- | -- |
| Total Operating Expenses | 2.19M | 2.26M | 1.13M | 560.50K | -179.90K |
| Operating Income | -2.19M | -2.26M | -1.13M | -560.50K | 179.90K |
| Income Before Tax | -3.79M | -2.06M | 35.40K | -549.40K | 168.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.79M | -2.06M | 35.40K | -549.40K | 168.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.79M | -2.06M | 35.40K | -549.40K | 168.00K |
| EBIT | -2.19M | -2.26M | -1.13M | -560.50K | 179.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.53 | -0.29 | 0.01 | -0.12 | 0.04 |
| Normalized Basic EPS | -0.33 | -0.18 | 0.00 | -0.08 | 0.02 |
| EPS Diluted | -0.53 | -0.29 | 0.01 | -0.12 | 0.04 |
| Normalized Diluted EPS | -0.33 | -0.18 | 0.00 | -0.08 | 0.02 |
| Average Basic Shares Outstanding | 7.08M | 7.04M | 6.17M | 4.47M | 4.46M |
| Average Diluted Shares Outstanding | 7.08M | 7.04M | 6.64M | 4.47M | 4.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |